Trial drug slows age-related macular degeneration in miceOctober 10th, 2008 - 1:16 pm ICT by ANI
Washington, Oct 10 (ANI): A new study in mice has shown that retinylamine a trial drug that has been tested in a medical school lab markedly slows the progression of age-related macular degeneration (AMD).
The findings, by researchers at the Case Western Reserve University School of Medicine, provide evidence for biochemical change in the retina that resemble AMD.
The study was led by postdoctoral researcher Akiko Maeda, an investigator in the lab of one of her co-authors, Krzysztof Palczewski.
Palczewski, who is chair and the John H. Hord Professor of Pharmacology at the School of Medicine, said that AMD currently isn”t usually treated until toward the end of the disease.
However, with the discovery in his lab by Maeda and her research team, retinylamine can potentially prevent the rapid degeneration of the eye, slowing the rate of progression of AMD.
As humans go through the aging process, it eventually affects the vision and a fraction of those cases will progress further and potentially develop AMD.
Through their work on mouse models, Maeda and her team have learned to modify the genes that establish the rate of changes related to AMD.
However, the biochemical trigger of these changes had not been understood until now as a result of the retinylamine treatments.
“We have proven this observation, genetically, biochemically and pharmacologically. Dr. Maeda, who studies retinal degenerative diseases in my lab and works to develop models that will facilitate the evaluation of the safety and effectiveness of drug candidates designed to combat retinal disease in humans, has done superb work in this area. We”re very excited about the potential this outcome represents,” Palczewski said.
“Until now, with the discovery in our lab, the genesis of that progression wasn”t known. Now we have the potential to intervene in the middle of the disease’’s advancement so we can prevent rapid degeneration of the eye. The importance of this work also is illustrated by the five-year K08 award made to Dr. Maeda by the National Eye Institute,” Palczewski said.
The study is reported in the prestigious Journal of Biological Chemistry. (ANI)
- Stem cell therapy for age-related macular degeneration may soon be a reality - Mar 25, 2011
- Indian origin scientist's gene therapy shows promise in slowing AMD - Apr 30, 2011
- Novel cell therapy slows down vision loss in eye disease - Apr 08, 2011
- Omega-3 in seafood may protect seniors' eyes - Dec 02, 2010
- Flatworm may help battle eye diseases - Aug 03, 2012
- Additional genes linked to age-related macular degeneration identified - Apr 13, 2010
- Drugs to treat age-related blindness - Feb 07, 2011
- Smoking 'worsens age-related macular degeneration' - Dec 31, 2009
- Study identifies key mechanisms in geographic atrophy - Feb 07, 2011
- It's never too late to stub the butt and save eyesight - Dec 31, 2009
- Potbellied men ' likelier to go blind' - Apr 01, 2011
- Grapes can stave off age-related blindness - Jan 15, 2012
- Compound likely to regenerate vision in humans - Jul 26, 2012
- Scientists create retina from human embryonic stem cells - May 27, 2010
- Second molecule in Alzheimer's toxic duo identified - Feb 04, 2011
Tags: age related macular degeneration, aging process, amd, case western reserve, case western reserve university, case western reserve university school of medicine, drug candidates, genes, hord, macular degeneration, maeda, medical school, mice, mouse models, pharmacology, retina, retinal degenerative diseases, retinal disease, school of medicine, western reserve university